[Significance of Quality of Life Evaluation for Glioma Patients].
No Shinkei Geka
; 49(3): 660-664, 2021 May.
Article
em Ja
| MEDLINE
| ID: mdl-34092572
ABSTRACT
Typically, overall and progression-free survival are used as endpoints in clinical tri-als investigating gliomas, while health-related quality of life(HRQOL)plays a key role in cancer research and may be useful for individual patient care. Previous studies have shown that HRQOL parameters can serve as independent prognostic factors for survival in patients with cancer, while recent studies have highlighted the usefulness of HRQOL in information management and decision-making in cancer treatment. However, a few studies have shown differences between patients' and physicians' perceptions of cancer treatment. In the future, physicians will be expected to recog-nize the importance of the QOL evaluation tool, not only in clinical trials, but also in general practice for gliomas, considering the characteristics of patients with brain tu-mors. In this study, we reviewed the methods of major HRQOL evaluation and sum-marized the first clinical trials incorporating QOL in glioma treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Qualidade de Vida
/
Glioma
Tipo de estudo:
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
Ja
Revista:
No Shinkei Geka
Ano de publicação:
2021
Tipo de documento:
Article